<DOC>
	<DOCNO>NCT02947503</DOCNO>
	<brief_summary>One approach prevent rise burden diabetes address issue gestational diabetes mellitus ( GDM ) . GDM grow prevalence 5-10 % ( even higher specific subgroup ) , pregnant population become old obese worldwide . GDM increase risk complication pregnancy , delivery long term , like type 2 diabetes ( T2D ) persistent obesity , mother child . Moreover , insulin add diet standard care GDM disadvantage mother ( maintenance hyperinsulinaemia , increase weight blood pressure ) child ( macrosomia , hypoglycaemia ) relate adverse pregnancy outcome . Metformin , insulin sensitizer target cause GDM , may essential benefit , suggest observational study . However , RCTs metformin ( early position treatment GDM ) still lack . The POEM study first Randomized control trial ( RCT ) GDM test hypothesis metformin , early give start diagnosis GDM , top diet lifestyle improve clinically relevant pregnancy outcomes mother child pregnancy , delivery long term - 20 year birth .</brief_summary>
	<brief_title>Pregnancy Outcomes : Effects Metformin Study ( POEM Study )</brief_title>
	<detailed_description>The POEM study design investigate effect metformin top diet lifestyle ( insulin rescue need ) GDM eight clinically relevant pregnancy outcomes delivery , summarize mean integrate , newly develop score , GDM Outcome Score ( GOS ) , relevant outcomes long term mother child . The investigator hypothesize metformin give woman GDM start diagnosis reduces risk result relevant health benefit mother child pregnancy , delivery , many year thereafter . The POEM study randomize control intervention study , consist three phase : - Phase A - inclusion two week delivery ; intervention study without exposure metformin mother ( unborn ) child : two arm randomization 1:1 allocation Diet + Lifestyle + Metformin ( DLM ) Diet + Lifestyle ( DL ) ; - Phase B - two week 1 year delivery ; intervention study exposure DLM v DL mother ; - Phase C - 1 20 year delivery ; observational extension study mother child without study medication .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Diabetes , Gestational</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Pregnant woman GDM define Fasting Plasma Glucose ( FPG ) &gt; 5,3 mMol and/or Oral Glucose Tolerance test ( OGTT ) Plasma glucose ( PG ) &gt; 7,8 mMol , two hour oral intake 75 gram glucose Written inform consent Age 1845 year Gestational age inclusion 1632 week Glycohemoglobin test ( HbA1c ) inclusion ≤ 48 mmol/mol ( 6.5 % Hb ) Diabetes mellitus pregnancy , except previous GDM Proteïnuria : Urine AlbumintoCreatinine Ratio ( UACR ) &gt; 35 mg/mmol screen Malignancy last 5 year inclusion , except nonmelanoma skin cancer Psychiatric and/or mood disorder potentially affect compliance treatment Chronic liver disease and/or Alanine aminotransferase aspartate transaminase ( ASAT ) and/or Alanine aminotransferase ( ALAT ) &gt; 3x Upper Limit Normal ( ULN ) . Chronic renal failure Glomerular filtration rate ( GFR ) &lt; 45 ml/min/1.73m2 Chronic pulmonary failure hypoxia Significantly uncontrolled hypertension Systolic blood pressure ( SBP ) &gt; 160 mm Hg despite medical treatment Chronic treatment corticosteroid Intolerance metformin and/or earlier use metformin pregnancy Membership POEM study group Severe foetal anomaly inclusion like major neural tube and/or cardiac malformation Ruptured membranes Multiple pregnancy Inability understand read Dutch language</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Gestational Diabetes</keyword>
	<keyword>Insulin Resistance</keyword>
	<keyword>Metformin</keyword>
	<keyword>Hyperinsulinaemia</keyword>
	<keyword>Prevention Complications</keyword>
	<keyword>Long Term Study</keyword>
	<keyword>Mother Child</keyword>
	<keyword>Health Benefits</keyword>
</DOC>